Fig. 7
Knockdown of Itga2 improved the efficacy of immune checkpoint blockade therapy. a and b. Forty-eight hours postinfection, Panc02 cells infected with sh-Control or sh-Itga2 were harvested for Western blotting analysis (a) and RT-PCR analysis (b). Data are shown as means ± SD (n = 3). sh-Control group was compared with sh-Itga2 group. Statistical analyses were performed with one-way ANOVA followed by Tukey’s multiple comparison’s tests. ***, P < 0.001. c. After 72 h of selection with puromycin, 5 × 106 Panc02 cells infected with sh-Control or sh-Itga2 were subcutaneously injected into the right dorsal flank of C57BL/6 mice. Mice with subcutaneous Panc02 tumors (n = 5/group) were treated with anti-PD-1 (200 μg) or nonspecific IgG for three times shown as the schematic diagram (c). d. The Panc02 tumors growth curves (n = 5/group). Groups were compared with each other. Compared groups were shown in the figures. Statistical analyses were performed with two-way ANOVA followed by Sidak’s multiple comparison’s tests. ***, P < 0.001. e. Kaplan-Meier percent survival curves for each group with different treatments. Groups were compared with each other. Compared groups were shown in the figures. Statistical analyses were performed with Gehan-Breslow-Wilcoxon test. ***, P < 0.001. f. At the end of treatment, the tumors excised from the mice were dissociated, and tumor cells were harvested for Flow cytometry analysis to detect the numbers of TILs. All data are shown as means ± SD (n = 5). Groups were compared with each other. Compared groups were shown in the figures. Statistical analyses were performed with one-way ANOVA followed by Tukey’s multiple comparison’s tests. *** P < 0.001. g. The immune infiltration level based on the expression of ITGA2 was searched by the TIMER web tool. P values as indicated